Drug interactions
Efavirenz + Polatuzumab vedotin
Severity: Minor
Efavirenz and Polatuzumab vedotin: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
The cytotoxic payload MMAE released from polatuzumab vedotin is a CYP3A4 substrate. Efavirenz, as a CYP3A4 inducer, may lower unconjugated MMAE exposure, though the effect of a moderate inducer is probably smaller than that of a strong one.
What this interaction means in plain words
Efavirenz and Polatuzumab vedotin have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Efavirenz belongs to Anti Virals; Polatuzumab vedotin belongs to Oncology.
Why it happens
Efavirenz induces CYP3A4, increasing metabolism of MMAE.
What to do
No dose adjustment is required. Monitor the lymphoma response.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Efavirenz and Polatuzumab vedotin, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Efavirenz
- Cobimetinib + Efavirenz Contraindicated
- Dienogest / estradiol valerate + Efavirenz Contraindicated
- Dihydroergotamine intranasal + Efavirenz Contraindicated
- Dihydroergotamine + Efavirenz Contraindicated
- Doravirine + Efavirenz Contraindicated
- Efavirenz + Elbasvir / grazoprevir Contraindicated
Other interactions of Polatuzumab vedotin
Frequently asked questions
Can I take Efavirenz with Polatuzumab vedotin?
MediHelp rates the interaction as minor. Efavirenz and Polatuzumab vedotin have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. The cytotoxic payload MMAE released from polatuzumab vedotin is a CYP3A4 substrate. Efavirenz, as a CYP3A4 inducer, may lower unconjugated MMAE exposure, though the effect of a moderate inducer is probably smaller than that of a strong one.
How serious is the interaction between Efavirenz and Polatuzumab vedotin?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No dose adjustment is required. Monitor the lymphoma response.
What other medicines interact with Efavirenz?
MediHelp also lists interactions of Efavirenz with, for example, Cobimetinib, Dienogest / estradiol valerate, Dihydroergotamine intranasal. The full list is on the Efavirenz page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
